Huntington National Bank Boosts Stake in Icon Plc (ICLR)

Huntington National Bank boosted its position in Icon Plc (NASDAQ:ICLR) by 5.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,630 shares of the medical research company’s stock after buying an additional 77 shares during the period. Huntington National Bank’s holdings in Icon Plc were worth $159,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. US Bancorp DE boosted its stake in shares of Icon Plc by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after buying an additional 251 shares during the period. Quantbot Technologies LP raised its position in shares of Icon Plc by 40.9% in the first quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock worth $161,000 after buying an additional 587 shares in the last quarter. IFP Advisors Inc raised its position in shares of Icon Plc by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares in the last quarter. Atria Investments LLC bought a new position in shares of Icon Plc during the first quarter worth $214,000. Finally, Trexquant Investment LP bought a new position in shares of Icon Plc during the first quarter worth $228,000. 91.65% of the stock is owned by hedge funds and other institutional investors.

Shares of Icon Plc (NASDAQ:ICLR) traded down 0.19% during mid-day trading on Friday, reaching $104.99. 208,371 shares of the company’s stock traded hands. The firm has a market cap of $5.67 billion, a price-to-earnings ratio of 21.30 and a beta of 0.60. Icon Plc has a one year low of $73.76 and a one year high of $109.32. The firm’s 50-day moving average is $101.46 and its 200 day moving average is $89.84.

Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.01. The business had revenue of $431 million during the quarter, compared to analyst estimates of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. Analysts predict that Icon Plc will post $5.32 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/huntington-national-bank-purchases-77-shares-of-icon-plc-iclr-updated-updated.html.

Several research firms have commented on ICLR. Credit Suisse Group reiterated an “outperform” rating and set a $102.00 price objective (up previously from $91.00) on shares of Icon Plc in a research report on Tuesday, June 6th. BidaskClub raised shares of Icon Plc from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. ValuEngine downgraded shares of Icon Plc from a “buy” rating to a “hold” rating in a research note on Wednesday, May 31st. Zacks Investment Research downgraded shares of Icon Plc from a “hold” rating to a “sell” rating in a research note on Wednesday, April 26th. Finally, Mizuho raised their price target on shares of Icon Plc from $104.00 to $108.00 and gave the stock a “neutral” rating in a research note on Thursday, July 27th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $108.38.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Institutional Ownership by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply